Download PDF
Klin Padiatr 2011; 223(06): 386-394
DOI: 10.1055/s-0031-1287837
Bericht
© Georg Thieme Verlag KG Stuttgart · New York

Interdisziplinäre S2-Therapieleitlinie der Juvenilen Idiopathischen Arthritis (2. Auflage)

Evidence and Consensus Based Treatment Guidelines 2010 for Juvenile Idiopathic Arthritis by the German Society of Paediatric Rheumatology
G. Dueckers
1   Zentrum für Kinder- und Jugendmedizin, HELIOS Klinikum Krefeld
,
N. Guellac
2   Bundeswehr, Zentralkrankenhaus, Koblenz
,
M. Arbogast
3   Rheumazentrum, Oberammergau
,
G. Dannecker
4   Olgahospital, Klinik für Kinder- und Jugendmedizin, Pädiatrie 1, Klinikum Stuttgart
,
I. Foeldvari
5   Hamburger Zentrum für Kinder- und Jugendrheumatologie, am Schön Klinik Eilbeck, Hamburg
,
M. Frosch
6   Zentrum für Kinder- und Jugendmedizin, Universität Münster
,
G. Ganser
7   St. Josef Stift, Zentrum für Kinder- und Jugendrheumatologie, Sendenhorst
,
A. Heiligenhaus
8   Uveitis Zentrum, Münster
,
G. Horneff
9   Asklepios Klink, Pädiatrie, Sankt Augustin
,
A. Illhardt
7   St. Josef Stift, Zentrum für Kinder- und Jugendrheumatologie, Sendenhorst
,
R. Krauspe
10   Klinik für Orthopädie, Universitätsklinikum Düsseldorf
,
B. Markus
11   Deutsche Rheuma Liga, e.V., Bonn
,
H. Michels
12   Deutsches Zentrum für Kinder- und Jugendrheumatologie, Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen
,
M. Schneider
13   Abteilung für Endokrinologie, Diabetologie und Rheumatologie, Universitätsklinikum Düsseldorf
,
W. Singendonk
14   Berufsverband, Kinder- und Jugendmedizin, Berlin
,
H. Sitter
15   Abteilung für Chirurgische Forschung, Universität Marburg
,
M. Spamer
12   Deutsches Zentrum für Kinder- und Jugendrheumatologie, Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen
,
N. Wagner
16   Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Aachen
,
T. Niehues
1   Zentrum für Kinder- und Jugendmedizin, HELIOS Klinikum Krefeld
› Author Affiliations
Further Information

Publication History

Publication Date:
19 October 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Standardisierung der Therapie der Juvenilen Idiopathischen Arthritis (JIA) hat zu einer Verbesserung der Lebensqualität von Kindern und Jugendlichen mit JIA geführt. Um die Versorgungsqualität dieser Patienten weiter zu erhöhen, ist eine Aktualisierung der bisherigen S2-Leitlinie von 2008 erforderlich.

Methodik:

Durch eine neue systematische Literaturanalyse (Stichwörter: juvenile idiopathic (rheumatoid) arthritis, therapy; Suchbegrenzungen (Limits) in PUBMED: humans, published in the last 3 years, all child: 0–18 years, clinical trial; Stichtag 15.01.2011) wurden 17 relevante Studien gefunden. Studien zur Diagnostik der JIA, Uveitis, Impfung, Transition wurden ausgeschlossen. Zu moderierten Konsensuskonferenzen wurden Vertreter folgender Fachgesellschaften und Vereinigungen eingeladen: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Die Konsensuskonferenzen fanden unter > 95% Teilnahme statt. Konsensus-Statements wurden formal per Nominale Gruppentechnik und im Delphiverfahren gewonnen.

Resultate:

Zu den Themen medikamentöse, symptomatische und chirurgische Therapie wurden aktualisierte Statements im Konsens erarbeitet und nach Kriterien evidenzbasierter Medizin bewertet. Neue, relevante Studien sind in der 2. Auflage der S2-Leitlinie für die Therapie der JIA berücksichtigt.

Abstract

Background:

Treatment of Juvenile Idiopathic Arthritis (JIA) has improved quality of life in children and adolescents with JIA. Standardisation of care offers the chance to improve the quality of care of those patients. New studies have been published after completion of our last treatment guideline (2007). An updated consensus process is mandatory.

Methods:

A systematic literature analysis in PUBMED (key words: juvenile idiopathic (rheumatoid) arthritis, therapy; limits: humans, published in the last 3 years, all child 0–18 years, clinical trial) revealed 17 relevant studies. Studies relating to diagnosis of JIA, Uveitis, vaccination, transition were excluded. Representatives nominated by scientific societies and organisations were invited to consensus conferences which were hosted by a professional moderator. The following societies were invited: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Consensus conferences were each attended by more than 95% of the nominated representatives. Consensus statements were confirmed by nominal group technique and Delphi method.

Results and Conclusion:

Updated consensus statements regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).

Schlüsselwörter

Juvenile Idiopathische Arthritis - evidenzbasierte Medizin - Therapieleitlinie - Kinder - Jugendliche - Konsens

Key words

juvenile idiopathic arthritis - evidence-based medicine - treatment guideline - children - adolescents - consensus

Supplementary Material

 

  • Literatur

  • 1 April KT, Feldman DE, Platt RW et al. Comparison between Children with Juvenile Idiopathic Arthritis (JIA) and their parents concerning perceived Quality of Life. Qual Life Res 2006; 15: 655-661
    CrossrefPubMedGoogle Scholar
  • 2 Beukelman T, Patkar NM, Saag KG et al. 2011; American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-482
    CrossrefPubMedGoogle Scholar
  • 3 Brinkman DM, de Kleer IM, ten Cate R et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007; 56: 2410-2421
    CrossrefPubMedGoogle Scholar
  • 4 Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A et al. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 2008; 67: 309-314
    PubMedGoogle Scholar
  • 5 de Jong Z, Munneke M, Zwinderman AH et al. Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 2003; 48: 2415-2424
    CrossrefPubMedGoogle Scholar
  • 6 Diak P, Siegel J, La Grenade L et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62: 2517-2524
    CrossrefPubMedGoogle Scholar
  • 7 Epps H, Ginnelly L, Utley M et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess 2005; 9 iii-iv, ix-x 1-59
    PubMedGoogle Scholar
  • 8 Feldman BM, Grundland B, McCullough L et al. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol 2000; 27: 226-233
    PubMedGoogle Scholar
  • 9 Foeldvari I, Szer IS, Zemel LS et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol 2009; 36: 174-182
    PubMedGoogle Scholar
  • 10 Gao JS, Wu H, Tian J. Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate. Zhonghua Er Ke Za Zhi 2003; 41: 435-438
    PubMedGoogle Scholar
  • 11 Giannini EH, Brewer EJ, Miller ML et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr 1990; 117: 645-652
    PubMedGoogle Scholar
  • 12 Giannini EH, Ilowite NT, Lovell DJ et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 2794-2804
    CrossrefPubMedGoogle Scholar
  • 13 Guellac N, Niehues T. Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis. Klin Padiatr 2008; 220: 392-402
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol 1983; 12: 325-330
    CrossrefPubMedGoogle Scholar
  • 15 Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol 2009; 28: 749-756
    CrossrefPubMedGoogle Scholar
  • 16 Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68: 519-525
    CrossrefPubMedGoogle Scholar
  • 17 Horneff G, Ebert A, Fitter S et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 2009; 48: 916-919
    CrossrefPubMedGoogle Scholar
  • 18 Horneff G, Forster J, Seyberth HW et al. Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee. Z Rheumatol 2000; 59: 365-369
    CrossrefPubMedGoogle Scholar
  • 19 Horneff G, Hospach T, Dannecker G et al. Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA’s report regarding malignancies in anti-TNF-treated patients from Aug 4, 2009. Z Rheumatol 2010; 69: 561-567
    CrossrefPubMedGoogle Scholar
  • 20 Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-1644
    CrossrefPubMedGoogle Scholar
  • 21 Hospach T, Haas JP, Huppertz HI et al. Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients. Z Rheumatol 2009; 68: 162-164
    CrossrefPubMedGoogle Scholar
  • 22 Ilowite N, Porras O, Reiff A et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-137
    CrossrefPubMedGoogle Scholar
  • 23 Imagawa T, Yokota S, Mori M et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2011; Epub ahead of print
    PubMedGoogle Scholar
  • 24 Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 142-146
    CrossrefPubMedGoogle Scholar
  • 25 Klepper SE. Effects of an eight-week physical conditioning program on disease signs and symptoms in children with chronic arthritis. Arthritis Care Res 1999; 12: 52-60
    CrossrefPubMedGoogle Scholar
  • 26 Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol 1984; 13: 342-350
    CrossrefPubMedGoogle Scholar
  • 27 Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986; 13: 118-123
    PubMedGoogle Scholar
  • 28 Laxer RM, Silverman ED, St-Cyr C et al. A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis. Clin Ther 1988; 10: 381-387
    PubMedGoogle Scholar
  • 29 Leak AM, Richter MR, Clemens LE et al. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 157-160
    PubMedGoogle Scholar
  • 30 Lequerre T, Quartier P, Rosellini D et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-308
    PubMedGoogle Scholar
  • 31 Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-769
    CrossrefPubMedGoogle Scholar
  • 32 Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-1504
    CrossrefPubMedGoogle Scholar
  • 33 Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54: 1987-1994
    CrossrefPubMedGoogle Scholar
  • 34 Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-820
    CrossrefPubMedGoogle Scholar
  • 35 Malleson PN, Bennett SM, MacKinnon M et al. Physical fitness and its relationship to other indices of health status in children with chronic arthritis. J Rheumatol 1996; 23: 1059-1065
    PubMedGoogle Scholar
  • 36 Manschwetus H. Quality standards and certification of patient education in rheumatology. Z Rheumatol 2003; 62: II21-II23
    PubMedGoogle Scholar
  • 37 Michels H. What is low-dose corticosteroid therapy in juvenile idiopathic arthritis? A worldwide, questionnaire-based survey. Z Rheumatol 2000; 59 (Suppl. 02) II/127-II/130
    PubMedGoogle Scholar
  • 38 Miller 3rd JJ. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980; 65: 989-994
    PubMedGoogle Scholar
  • 39 Niehues T, Horneff G, Michels H et al. Evidence-based use of methotrexate in children with rheumatic disorders. Consensus statement of the Working Group for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and the Working Group Pediatric Rheumatology Austria. Z Rheumatol 2004; 63: 147-158
    CrossrefPubMedGoogle Scholar
  • 40 Picco P, Gattorno M, Buoncompagni A et al. 6-methylprednisolone ‘mini-pulses’: a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scand J Rheumatol 1996; 25: 24-27
    CrossrefPubMedGoogle Scholar
  • 41 Powell M, Seid M, Szer IS. Efficacy of custom foot orthotics in improving pain and functional status in children with juvenile idiopathic arthritis: a randomized trial. J Rheumatol 2005; 32: 943-950
    PubMedGoogle Scholar
  • 42 Prieur AM. The place of corticosteroid therapy in juvenile chronic arthritis in 1992. J Rheumatol Suppl 1993; 37: 32-34
    PubMedGoogle Scholar
  • 43 Prince FH, Twilt M, Jansen-Wijngaarden NC et al. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007; 66: 704-705
    CrossrefPubMedGoogle Scholar
  • 44 Prince FH, Twilt M, ten Cate R et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009; 68: 635-641
    CrossrefPubMedGoogle Scholar
  • 45 Rasnake LK, Mervis K, Belpedio K et al. Child and parents perceptions of child health-related quality of life in rheumatic disease: discrepancy and congruencies for ill and well days. Pediatr Rheumatol Online J 2003; 1 Abstract No. 187
    PubMedGoogle Scholar
  • 46 Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096-3106
    CrossrefPubMedGoogle Scholar
  • 47 Ruperto N, Lovell DJ, Quartier P et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 1792-1802
    CrossrefPubMedGoogle Scholar
  • 48 Ruperto N, Lovell DJ, Quartier P et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-391
    CrossrefPubMedGoogle Scholar
  • 49 Ruperto N, Murray KJ, Gerloni V et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-2201
    CrossrefPubMedGoogle Scholar
  • 50 Ruperto N, Nikishina I, Pachanov ED et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 2005; 52: 563-572
    CrossrefPubMedGoogle Scholar
  • 51 Silverman E, Mouy R, Spiegel L et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352: 1655-1666
    CrossrefPubMedGoogle Scholar
  • 52 Simard JF, Neovius M, Hagelberg S et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62: 3776-3782
    CrossrefPubMedGoogle Scholar
  • 53 Singh-Grewal D, Schneiderman-Walker J, Wright V et al. The effects of vigorous exercise training on physical function in children with arthritis: a randomized, controlled, single-blinded trial. Arthritis Rheum 2007; 57: 1202-1210
    CrossrefPubMedGoogle Scholar
  • 54 Singh-Grewal D, Wright V, Bar-Or O et al. Pilot study of fitness training and exercise testing in polyarticular childhood arthritis. Arthritis Rheum 2006; 55: 364-372
    CrossrefPubMedGoogle Scholar
  • 55 Stephens S, Singh-Grewal D, Bar-Or O et al. Reliability of exercise testing and functional activity questionnaires in children with juvenile arthritis. Arthritis Rheum 2007; 57: 1446-1452
    CrossrefPubMedGoogle Scholar
  • 56 Stoeber E, Sanger L. Experiences with indomethacin in long-term therapy of juvenile rheumatoid arthritis. Arzneimittelforschung 1971; 21: 1865-1866
    PubMedGoogle Scholar
  • 57 Takken T, Van Der Net J, Kuis W et al. Aquatic fitness training for children with juvenile idiopathic arthritis. Rheumatology (Oxford) 2003; 42: 1408-1414
    CrossrefPubMedGoogle Scholar
  • 58 Takken T, van der Net J, Kuis W et al. Physical activity and health related physical fitness in children with juvenile idiopathic arthritis. Ann Rheum Dis 2003; 62: 885-889
    CrossrefPubMedGoogle Scholar
  • 59 Toledo MM, Martini G, Gigante C et al. Is there a role for arthroscopic synovectomy in oligoarticular juvenile idiopathic arthritis?. J Rheumatol 2006; 33: 1868-1872
    PubMedGoogle Scholar
  • 60 van Rossum MA, Fiselier TJ, Franssen MJ et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41: 808-816
    CrossrefPubMedGoogle Scholar
  • 61 van Rossum MA, van Soesbergen RM, Boers M et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007; 66: 1518-1524
    CrossrefPubMedGoogle Scholar
  • 62 Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009; 27: 1017-1025
    PubMedGoogle Scholar
  • 63 Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006
    CrossrefPubMedGoogle Scholar
  • 64 Zulian F, Martini G, Gobber D et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2003; 42: 1254-1259
    CrossrefPubMedGoogle Scholar
  • 65 Zulian F, Martini G, Gobber D et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004; 43: 1288-1291
    CrossrefPubMedGoogle Scholar
  • 66 West CA, Besier T, Borth-Bruhns T et al. Effectiveness of a Family-oriented Rehabilitation Program on the Quality of Life of Parents of Chronically Ill Children. Klin Padiatr 2009; 221: 241-246
    Article in Thieme ConnectPubMedGoogle Scholar